Servier's takeover bid of Egis proves successful


Servier’s Voluntary Public Offer for the outstanding shares in Egis Pharmaceuticals plc has closed.  Valid acceptances total in excess of 3,543,617 shares, giving Servier ownership and control of over 96.43% of Egis

Suresnes, France, November 7, 2013 – Arts et Techniques du Progrès (“ATP”), a wholly owned subsidiary of the Servier Group, announces that its Voluntary Public Offer (the Offer) for all outstanding shares of Egis Pharmaceuticals plc (Egis), which was announced on 24 September 2013, closed on 5 November 2013.  Valid acceptances of the Offer totaled 3,543,617 ordinary voting shares (Shares) of Egis.

Together with the 3,963,922 shares or 50.91% of Egis Shares owned by Servier Group prior to the Offer, Servier Group now owns and controls 7,507,539 Shares that represents a 96.43% ownership interest in Egis.  ATP will soon launch the squeeze-out process of the minority shareholders of Egis in line with the relevant provisions of the Hungarian capital market regulations. ATP will publish the details of the squeeze-out process on Egis’ website (, on KBC Securities’ website (, on the website of the Budapest Stock Exchange ( and on the website of the National Bank of Hungary as legal successor to the Hungarian Financial Supervisory Authority (

The process of payment to Egis shareholders who have validly accepted the Offer will commence on 12 November 2013.


Media Contacts

Jon Coles   
Brunswick Group
Tel: +44 20 7404 5959

Pip Green
Brunswick Group
Tel: +44 20 7404 5959

In Budapest:
Imre Varga  
Noguchi Porter Novelli
Tel: +36 30 433 9092   

Balazs Szanto
Noguchi Porter Novelli
Tel: +36 30 934 5362

Investor Contacts
Tel: +36 1 483-4088
Fax: +36 1 483-4089

Ádám Hegyi   
KBC Securities Hungary   
Tel: +36 1 483 4086   

Miklós Bónis
KBC Securities Hungary
Tel: +36 1 483 4083

Background information

About Servier Group

Servier Group is a privately-held research-led pharmaceutical group, with more than 20,000 employees, including 3,000 in R&D, around the world and with its products available in more than 140 countries. Organized as a foundation and deeply committed to research, it reinvests a large portion of its turnover in the research and development of innovative medications.

About Egis

Egis, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe and CIS countries. The company focuses on research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders. The company sells its products in many countries across the world through business partners and strong subsidiary companies network.

Download the English press release

Download the Hungarian press release